These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 1609773

  • 21. Discrepant increase in factor VIII: C and von Willebrand factor after DDAVP infusion in a patient with variant von Willebrand's disease.
    Casonato A, Sartori MT, Pontara E, Bertomoro A, Dannhäuser D, Girolami.
    Blood Coagul Fibrinolysis; 1991 Aug; 2(4):567-73. PubMed ID: 1768767
    [Abstract] [Full Text] [Related]

  • 22. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A, Sartorello F, Pontara E, Gallinaro L, Bertomoro A, Grazia Cattini M, Daidone V, Szukowska M, Pagnan A.
    Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
    [Abstract] [Full Text] [Related]

  • 23. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A, van der Planken M, Schroyens W, Berneman Z, Michiels JJ.
    Acta Haematol; 2009 Dec; 121(2-3):145-53. PubMed ID: 19506361
    [Abstract] [Full Text] [Related]

  • 24. A variant of von Willebrand's disease characterized by recessive inheritance and missing triplet structure of von Willebrand factor multimers.
    Mannucci PM, Lombardi R, Pareti FI, Solinas S, Mazzucconi MG, Mariani G.
    Blood; 1983 Nov; 62(5):1000-5. PubMed ID: 6605165
    [Abstract] [Full Text] [Related]

  • 25. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A, Berneman Z, Schroyens W, Michiels JJ.
    Acta Haematol; 2009 Nov; 121(2-3):128-38. PubMed ID: 19506359
    [Abstract] [Full Text] [Related]

  • 26. Family studies of patients with reduced ristocetin aggregation and abnormalities of factor VIII and/or platelet function.
    Ekert H, Ananthakrishnan R, Muntz RH, Dowling S, D'Souza S.
    Thromb Haemost; 1976 Aug 31; 36(1):78-85. PubMed ID: 1087478
    [Abstract] [Full Text] [Related]

  • 27. Type II H von Willebrand disease: new structural abnormality of plasma and platelet von Willebrand factor in a patient with prolonged bleeding time and borderline levels of ristocetin cofactor activity.
    Federici AB, Mannucci PM, Lombardi R, Lattuada A, Colibretti ML, Dent JA, Zimmerman TS.
    Am J Hematol; 1989 Dec 31; 32(4):287-93. PubMed ID: 2510503
    [Abstract] [Full Text] [Related]

  • 28. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ, van Vliet HH.
    Acta Haematol; 2009 Dec 31; 121(2-3):154-66. PubMed ID: 19506362
    [Abstract] [Full Text] [Related]

  • 29. An atypical von Willebrand's disease with hyperreactivity of platelet aggregation.
    Niiya K, Kubonishi I, Taguchi H, Miyoshi I.
    Acta Haematol; 1984 Dec 31; 71(3):158-64. PubMed ID: 6424380
    [Abstract] [Full Text] [Related]

  • 30. Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications.
    Pérez-Rodríguez A, García-Rivero A, Lourés E, López-Fernández MF, Rodríguez-Trillo A, Batlle J.
    Haematologica; 2009 May 31; 94(5):679-86. PubMed ID: 19286880
    [Abstract] [Full Text] [Related]

  • 31. Re-evaluation of the therapeutic efficacy of DDAVP in type IIB von Willebrand's disease.
    Casonato A, Pontara E, Dannhaeuser D, Bertomoro A, Sartori MT, Zerbinati P, Girolami A.
    Blood Coagul Fibrinolysis; 1994 Dec 31; 5(6):959-64. PubMed ID: 7893933
    [Abstract] [Full Text] [Related]

  • 32. Clinical significance of inhibitors in acquired von Willebrand syndrome.
    Mohri H, Motomura S, Kanamori H, Matsuzaki M, Watanabe S, Maruta A, Kodama F, Okubo T.
    Blood; 1998 May 15; 91(10):3623-9. PubMed ID: 9572997
    [Abstract] [Full Text] [Related]

  • 33. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Clin Appl Thromb Hemost; 2006 Jul 15; 12(3):277-95. PubMed ID: 16959681
    [Abstract] [Full Text] [Related]

  • 34. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
    Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van Vliet HH.
    Acta Haematol; 2009 Jul 15; 121(2-3):85-97. PubMed ID: 19506353
    [Abstract] [Full Text] [Related]

  • 35. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease.
    Holmberg L, Nilsson IM, Borge L, Gunnarsson M, Sjörin E.
    N Engl J Med; 1983 Oct 06; 309(14):816-21. PubMed ID: 6412139
    [Abstract] [Full Text] [Related]

  • 36. Development of an inhibitor specific to factor VIII: coagulant activity in a patient with platelet-type von Willebrand's disease.
    Castella A, Miller JL, Neuberg RW, Gawryl MS, Hoyer LW.
    Am J Clin Pathol; 1983 Nov 06; 80(5):745-9. PubMed ID: 6416054
    [Abstract] [Full Text] [Related]

  • 37. First report of combined factor VII Padua defect and von Willebrand's disease due to casual association of the two defects.
    Girolami A, Pontara E, Dannhauser D, Bertomoro A, Ferasin S, Piccolo M, Casonato A.
    Blood Coagul Fibrinolysis; 1993 Feb 06; 4(1):177-81. PubMed ID: 8457648
    [Abstract] [Full Text] [Related]

  • 38. Heat-treated factor VIII/von Willebrand factor concentrate in platelet-type von Willebrand's disease.
    Takahashi H, Tatewaki W, Nagayama R, Hanano M, Tamura M, Yamaguchi T, Takizawa S, Wada K, Shibata A.
    Haemostasis; 1987 Feb 06; 17(6):353-60. PubMed ID: 3123334
    [Abstract] [Full Text] [Related]

  • 39. Type IIB mutation His-505-->Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib.
    Rabinowitz I, Randi AM, Shindler KS, Tuley EA, Rustagi PK, Sadler JE.
    J Biol Chem; 1993 Sep 25; 268(27):20497-501. PubMed ID: 8376405
    [Abstract] [Full Text] [Related]

  • 40. Further characterization of platelet-type von Willebrand's disease in Japan.
    Takahashi H, Handa M, Watanabe K, Ando Y, Nagayama R, Hattori A, Shibata A, Federici AB, Ruggeri ZM, Zimmerman TS.
    Blood; 1984 Dec 25; 64(6):1254-62. PubMed ID: 6333901
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.